alexa Dealing With Non-cardiac Comorbidities In Advanced Heart Failure Patients: The Role Of β-blockers As Adjunct In The Conventional Therapy In A Teaching Hospital In Ghana | 16625
ISSN: 2155-9880

Journal of Clinical & Experimental Cardiology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

4th International Conference on Clinical & Experimental Cardiology

Charles Anane
Posters: J Clin Exp Cardiolog
DOI: 10.4172/2155-9880.S1.020
Abstract
Background: Non-cardiac comorbidities are frequent in advanced heart failure patients and are strongly associated with adverse clinical outcomes. Therefore, if these comorbidies are recognized and managed well, although this may complicate conventional treatment, outcomes in these high-risk heart failure patients may be greatly improved Objective: To assess the impact of non-cardiac comorbidities on survival of advanced heart failure patients using β-blockers as adjunct in the conventional therapy. Methods Design: Cohort study involving patients with advanced heart failure at the Cardiac Clinic of KATH. All the patients enrolled had Left Ventricular Ejection Fraction (LVEF) of ≤30% and were 30 years or above in age. Patients were excluded from the study if they were on β-blocker already. Patients: The study involved 583 patients with mean age 62 years ?14.5 SD (95% CI, 60.8-63.2). 312 (54%) were NYHA class III and 271(46%) were NYHA class IV. 51% were females whilst 49% were males. The patients were assigned to Carvedilol, Bisoprolol and Control. Survival from heart failure in the presence non-cardiac comorbidities was the primary end point. Survival was determined based on five (5) non-cardiac comorbidities present i.e. diabetes, chronic kidney disease, hypertension, chronic atrial fibrillation and pneumonia. Results: 11.5% of the patients had diabetes, 7.4% chronic kidney disease, 4.8% had chronic atrial fibrillation. 14.2% had hypertension, 2.2% had pneumonia and 1.9% were anaemic. Other comorbidities observed in the study were 2.6% renal impairment, 1.1% had stroke, 1.5% and 0.3% had HIV/AIDs and tuberculosis respectively whilst 52.5% of the patients presented with no comorbidity other than their advanced heart failure. The overall mortality rate after 6 months of therapy was 10.6% in the Carvedilol group, 11.5% in the Bisoprolol group and 25.5% in the Control group. Carvedilol reduced mortality from 36.1% at base line to 10.6% (25.5% reduction in death risk). Bisoprolol reduced mortality from 34.0% to 11.5% (23.0% reduction in death risk). With control, mortality reduced from 47.0% to 25.5% (21.5 % reduction in death risk) p < 0.001. Survival analysis using log rank test showed that patients on carvedilol had a higher survival rate compared to those on bisoprolol and control. Conclusion: Reduced mortality and increased survival of the patients with non-cardiac comorbidities were significantly achieved with beta blockers as adjunct to conventional therapy at the cardiac clinic
Biography
Charles Anane is an alumnus of the Kwame Nkrumah University of Science and Technology, Ghana. He has qualified as a Pharmacist in 1987 and joined the WHO working committee on Inventory Control of Medicines in Government hospitals throughout the country and coordinated the documentation on Inventory Policy of the Ministry of Health. He is a Clinical Pharmacist and currently holds Ph.D. in Clinical Pharmacy. He is a deputy director of pharmaceutical services at the KomfoAnokye Teaching Hospital and a fellow of the Ghana College of Pharmacists. He has published more than 31 scientific papers in reputed international peer-reviewed journals up to date
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7